Short-Term Safety of Booster Immunization With BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers.
BNT162b2
COVID-19
antibodies
booster
side-effects
Journal
Open forum infectious diseases
ISSN: 2328-8957
Titre abrégé: Open Forum Infect Dis
Pays: United States
ID NLM: 101637045
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
22
09
2021
accepted:
30
12
2021
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
16
2
2022
Statut:
epublish
Résumé
This study demonstrated a favorable short-term safety profile after a third dose of the BNT162b2 vaccine among healthcare workers (HCWs). There were more frequent local reactions and less systemic reactions compared to the second dose. The HCWs who reported reactions had higher prebooster titer of anti-S1 antibodies compared to those who reported no reactions.
Identifiants
pubmed: 35165656
doi: 10.1093/ofid/ofab656
pii: ofab656
pmc: PMC8755369
doi:
Types de publication
Journal Article
Langues
eng
Pagination
ofab656Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America.
Références
Lancet Infect Dis. 2021 Jul;21(7):939-949
pubmed: 33930320
JAMA. 2021 Jun 22;325(24):2457-2465
pubmed: 33956048
N Engl J Med. 2021 Apr 15;384(15):1412-1423
pubmed: 33626250
Nature. 2021 Aug;596(7870):109-113
pubmed: 34182569
N Engl J Med. 2021 Sep 16;385(12):1078-1090
pubmed: 34432976
Lancet. 2021 May 15;397(10287):1819-1829
pubmed: 33964222
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
Vaccines (Basel). 2021 Sep 01;9(9):
pubmed: 34579214